---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-003832"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:07:55.358534+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular reports positive 32-week DME data; FDA aligns on single Phase 3; cash runway into 2028

## Summary
- Cash, equivalents, securities $506M as of Dec 31; cash runway extended to 2028.
- SPECTRA Part 1 (DME): 4D-150 well tolerated, no intraocular inflammation; high dose +8.4 letters BCVA, -194 µm CST; mean 0.6 supplemental injections vs 4.0 for aflibercept.
- FDA: single Phase 3 trial (300-400 patients) acceptable for BLA for 4D-150 in DME; SPECTRA Part 2 no longer needed.
- Pipeline refocus: core 4D-150 (wet AMD/DME) and 4D-710 (CF); discontinue 4D-110 and 4D-125; reduce investment in 4D-175/725/310 pending partnerships.
- Phase 3 4FRONT trials for wet AMD start Q1 and Q3 2025; topline data expected H2 2027.

## SEC filing metadata
- accession: 0000950170-25-003832
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/0000950170-25-003832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/fdmt-20250110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-003832
- JSON: https://secwatch.observer/filing/0000950170-25-003832.json
- Plain text: https://secwatch.observer/filing/0000950170-25-003832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.